Special Issue

Targeted Therapy of Glioma: Current Developments in Targeted Drug Delivery Systems

Message from the Guest Editor

Despite many years of efforts, gliblastoma multiforme remains one of the most difficult types of cancer to treat. Current therapies remain unsatisfactory, due in part to the difficulty of drug delivery to the central nervous system across the blood–brain barrier (BBB) and the lack of selective action. One rational solution is the use of targeted therapy, which not only selectively destroys glioma cells but also allows them to cross the BBB. The aim of this Special Issue, entitled "Targeted Therapy of Glioma: Current Developments in Targeted Drug Delivery System," is to present the latest solutions for targeting therapeutic agents to glioma cells. This Special Issue welcomes submissions of original research articles, review papers, case studies, and clinical trials concerning new assessment methods, drugs, and targeting factors that can increase the effectiveness of glioma therapy and extend the lifespan and quality of life of patients.

Guest Editor

Prof. Dr. Łukasz Uram

Department of Inorganic and Analytical Chemistry, Rzeszów University of Technology, Rzeszow, Poland

Deadline for manuscript submissions

31 July 2026

Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed

mdpi.com/si/249364

Brain Sciences
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
brainsci@mdpi.com

mdpi.com/journal/brainsci

Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed

mdpi.com/journal/brainsci

MDPI

About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.